Renosen Pharmaceuticals Private Limited has submitted a revised disclosure to BSE Limited regarding the release of pledge on 4,00,000 equity shares of Senores Pharmaceuticals Limited under Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance Update

The revised disclosure, dated March 12, 2026, was submitted following BSE's email dated March 10, 2026, which observed that the earlier disclosure dated February 16, 2026, did not specify the "reason for encumbrance." The exchange had requested clarification on the reason for creation, release, or invocation of pledged shares.

Pledge Release Details

The disclosure pertains to the release of pledge on 4,00,000 equity shares of Senores Pharmaceuticals Limited. The key details of the transaction are presented below:

Current Shareholding Position

Renosen Pharmaceuticals Private Limited, formerly known as Senores Lifesciences Pvt. Ltd., currently holds 27,08,719 equity shares in Senores Pharmaceuticals Limited, representing 5.8817% of the total share capital. The company is classified as a promoter group entity in the shareholding structure.

Promoter Group Holdings

The disclosure also provides a comprehensive overview of the promoter and promoter group holdings in Senores Pharmaceuticals Limited:

Corporate Information

The disclosure was signed by Swapnil Jatinbhai Shah, Director of Renosen Pharmaceuticals Private Limited (DIN: 05259821), and submitted to BSE Limited under scrip code 544319. Senores Pharmaceuticals Limited is listed on both BSE Limited and National Stock Exchange of India Limited.

The revised disclosure ensures compliance with SAST regulations and provides transparency regarding the encumbrance activities of promoter group entities.

Senores pharmaceuticals Limited has issued a corporate guarantee of USD 4.1 million to support credit facilities for its wholly-owned US subsidiary. The guarantee was provided to HDFC Bank Limited on March 03, 2026, as part of the company's financial support structure for its international operations.

Corporate Guarantee Details

The pharmaceutical company has extended the guarantee for credit facilities availed by Senores Pharmaceuticals Inc., USA from HDFC Bank Limited. The guarantee covers an amount up to USD 4,100,000 (US Dollars Four Million One Hundred Thousand Only) and represents a significant financial commitment to support the subsidiary's operations.

Regulatory Compliance and Disclosure

The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled its disclosure obligations by providing detailed information about the guarantee arrangement to both BSE Limited and National Stock Exchange of India Limited.

Promoter Interest and Terms

The company has disclosed that promoters and promoter groups have interest in this transaction to the extent of their directorship in the wholly-owned subsidiary. However, the corporate guarantee has been extended at arm's length, ensuring compliance with regulatory requirements for related party transactions.

Financial Impact Assessment

According to the company's disclosure, the corporate guarantee currently has no impact on Senores Pharmaceuticals Limited other than its disclosure in the financial statements as a contingent liability. The guarantee will remain valid until the closure of the credit facilities or the tenure of the credit facilities, whichever occurs earlier.

The corporate guarantee arrangement demonstrates the company's commitment to supporting its international subsidiary's growth and operational requirements while maintaining transparency with stakeholders through proper regulatory disclosures.